Related content

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

By Venturini M.   Bighin C.   Monfardini S.   Cappuzzo F.   Olmeo N.   Durando A.   Puglisi F.   Nicoletto O.   Lambiase A.   Mastro L.  

Breast Cancer Research and Treatment, Vol. 95, Iss. 1, 2006-01 ,pp. : 45-53

Springer Publishing Company

Access to resources Recommend Favorite

Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer

By Buzdar A.  

Breast Cancer Research and Treatment, Vol. 73, Iss. 2, 2002-05 ,pp. : 161-175

Springer Publishing Company

Access to resources Recommend Favorite

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

By Gasparini Giampietro   Gion Massimo   Mariani Luigi   Papaldo Paola   Crivellari Diana   Filippelli Gianfranco   Morabito Alessandro   Silingardi Vittorio   Torino Francesco   Spada Antonella   Zancan Matelda   Sio Livia   Caputo Antonio   Cognetti Francesco   Lambiase Antonio   Amadori Dino  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 355-365

Springer Publishing Company

Access to resources Recommend Favorite

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

By Riemsma Rob  

Breast Cancer Research and Treatment, Vol. 123, Iss. 1, 2010-08 ,pp. : 9-24

Springer Publishing Company

Access to resources Recommend Favorite

Postmenopausal Metastatic Breast Cancer: A Review of First-Line Treatment Options

By Assersohn L.   Johnston S.R.D.  

American Journal of Cancer, Vol. 2, Iss. 2, 2003-01 ,pp. : 95-109

Adis International

Access to resources Recommend Favorite